SCHEMBL3343772

SCHEMBL3343772

Cl[Pt].NCCNCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5314937 0.88 CA12 (1.00)
SCHEMBL15381 0.88
Trientine SCHEMBL13685489 0.85 CA12 (0.85)
SCHEMBL581603 0.84 CA12 (1.00)
SCHEMBL25342018 0.84 CA12 (1.00)
SCHEMBL25342922 0.84 CA12 (1.00)
SCHEMBL15797 0.84 CA12 (1.00)
Ammonia Solution, Strong SCHEMBL902204 0.84
SCHEMBL181401 0.84 CA12 (1.00)
SCHEMBL7888125 0.84 CA12 (0.91)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578450-A4 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRAL (AU) 2009-06-17 EP claimed
US-20060127310-A1 Amplification of biotin-mediated targeting ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. 2006-06-15 US claimed
EP-1578450-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING Access Pharmaceuticals Australia Pty Ltd (AU) 2005-09-28 EP claimed
WO-2004045647-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) 2004-06-03 WO claimed
EP-1813609-B1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING SELECTIVE AURORA-A INHIBITORY EFFECT MSD KK (JP) 2013-06-19 EP disclosed
WO-2010111056-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-09-30 WO disclosed
WO-2010067888-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed
EP-1578450-A4 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRAL (AU) 2009-06-17 EP disclosed
EP-1828165-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-09-05 EP disclosed
US-20060127310-A1 Amplification of biotin-mediated targeting ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD. 2006-06-15 US disclosed
WO-2006046735-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 WO disclosed
EP-1578450-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING Access Pharmaceuticals Australia Pty Ltd (AU) 2005-09-28 EP disclosed
WO-2004045647-A1 AMPLIFICATION OF BIOTIN-MEDIATED TARGETING ACCESS PHARMACEUTICALS AUSTRALIA PTY LTD (AU) 2004-06-03 WO disclosed
EP-1261356-A2 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH PLATINUM COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2002-12-04 EP disclosed
EP-1261374-A2 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH FURTHER ANTI-CANCER AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2002-12-04 EP disclosed
US-6475791-B1 Uses for DNA structure-specific recognition protein MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-11-05 US disclosed
WO-2001064252-A2 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH FURTHER ANTI-CANCER AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-07 WO disclosed
WO-2001064226-A2 FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH PLATINUM COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-07 WO disclosed
US-5705334-A PREDICTING CYTOTOXICITY OF CANCER DRUGS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1998-01-06 US disclosed